Form D · Biotechnology
OX2 Therapeutics, Inc.
Minneapolis, MN · CIK 0001704490
Offering snapshot reported Sep 22, 2020 · SEC filing
- Reported sold
- $649K Offering amount: $750K
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 20, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 22, 2020 | Initial | $649,415 | No comparison | 15 | SEC filing |
| May 17, 2017 | Initial | $305,002 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-375949
Source: Form D, filed Sep 22, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sumant Dhawan | Director, Executive |
| Andrea Hunt | Director |
| Jeff Liter | Executive, Promoter |
| Thomas Martinson | Director |
| Christopher Moertel | Director, Executive |
| Ben Oehler | Director |
| Mike Olin | Director, Executive |
| Rob Parish | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1621 E. Hennepin Avenue Suite 290
Minneapolis, MN, 55414
Minneapolis, MN, 55414